Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Publishes Phase 3 PROMIS Results on CMS I-neb for NCFB Patients
Details : Colistimethate sodium cell membrane inhibitor, antibiotic drug, which is currently being evaluated for the treatment of non-cystic fibrosis bronchiectasis chronically infected with P. aeruginosa.
Product Name : CMS
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 13, 2024
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTO...
Product Name : L-CsA
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Pari
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
Details : Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease...
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Product Name : Xadago
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 05, 2021
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients compared to placebo.
Product Name : Promixin
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 09, 2021
Lead Product(s) : Colistimethate Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A new FDA Fast Track designation for Zambon
Details : FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company initiated BOSTON-4 phase 2 multi-center clinical study of Liposomal Cyclosporine A for Inhalation (L‑CsA‑i) for the treatment of bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic stem cell transplant (alloHSCT).
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 20, 2020
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable